395 related articles for article (PubMed ID: 17640385)
21. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Rinfret S; Behlouli H; Eisenberg MJ; Humphries K; Tu JV; Pilote L
Am Heart J; 2008 Feb; 155(2):316-23. PubMed ID: 18215603
[TBL] [Abstract][Full Text] [Related]
22. No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease.
Scheffer PG; Schindhelm RK; van Verschuer VM; Groenemeijer M; Simsek S; Smulders YM; Nanayakkara PW
Neth J Med; 2013 Sep; 71(7):359-65. PubMed ID: 24038561
[TBL] [Abstract][Full Text] [Related]
23. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Bang CN; Gislason GH; Greve AM; Torp-Pedersen C; Køber L; Wachtell K
Eur J Prev Cardiol; 2014 Mar; 21(3):330-8. PubMed ID: 23012689
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
Jacobson TA; Wertz DA; Kuznik A; Cziraky M
Curr Med Res Opin; 2013 Jul; 29(7):773-81. PubMed ID: 23647370
[TBL] [Abstract][Full Text] [Related]
25. Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Strandberg TE; Holme I; Faergeman O; Kastelein JJ; Lindahl C; Larsen ML; Olsson AG; Pedersen TR; Tikkanen MJ;
Am J Cardiol; 2009 May; 103(10):1381-5. PubMed ID: 19427432
[TBL] [Abstract][Full Text] [Related]
26. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Freeman SR; Drake AL; Heilig LF; Graber M; McNealy K; Schilling LM; Dellavalle RP
J Natl Cancer Inst; 2006 Nov; 98(21):1538-46. PubMed ID: 17077356
[TBL] [Abstract][Full Text] [Related]
27. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion.
Naji F; Suran D; Kanic V; Vokac D; Sabovic M
Int Heart J; 2009 Mar; 50(2):153-60. PubMed ID: 19367026
[TBL] [Abstract][Full Text] [Related]
28. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
Arsenault BJ; Boekholdt SM; Hovingh GK; Hyde CL; DeMicco DA; Chatterjee A; Barter P; Deedwania P; Waters DD; LaRosa JC; Pedersen TR; Kastelein JJ;
Circ Cardiovasc Genet; 2012 Feb; 5(1):51-7. PubMed ID: 22135385
[TBL] [Abstract][Full Text] [Related]
29. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
30. Differences between statins on clinical endpoints: a population-based cohort study.
Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
[TBL] [Abstract][Full Text] [Related]
31. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Perreault S; Blais L; Dragomir A; Bouchard MH; Lalonde L; Laurier C; Collin J
Eur J Clin Pharmacol; 2005 Oct; 61(9):667-74. PubMed ID: 16151763
[TBL] [Abstract][Full Text] [Related]
32. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
33. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Päivä H; Thelen KM; Van Coster R; Smet J; De Paepe B; Mattila KM; Laakso J; Lehtimäki T; von Bergmann K; Lütjohann D; Laaksonen R
Clin Pharmacol Ther; 2005 Jul; 78(1):60-8. PubMed ID: 16003294
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Neuhaus O; Hartung HP
Expert Rev Neurother; 2007 May; 7(5):547-56. PubMed ID: 17492904
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study.
Ghayour-Mobarhan M; Lamb DJ; Vaidya N; Livingstone C; Wang T; Ferns GA
Angiology; 2005; 56(1):61-8. PubMed ID: 15678257
[TBL] [Abstract][Full Text] [Related]
36. Benefits and menaces related to the use of statins in patients after renal transplantation.
Chmielewski M; Zdrojewski Z; Rutkowski B
Ann Transplant; 2002; 7(2):6-10. PubMed ID: 12416466
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Farnier M; Portal JJ; Maigret P
J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
[TBL] [Abstract][Full Text] [Related]
38. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
39. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Huang BZ; Chang JI; Li E; Xiang AH; Wu BU
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040693
[TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Sharma R; Mahajan M; Singh B; Bal BS; Kant R
J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
